Archives of Medical Research
Volume 41, Issue 4 , Pages 261-268 , May 2010

Immunohistochemical Analysis of Prostate Apoptosis Response-4 (Par-4) in Mexican Women with Breast Cancer: A Preliminary Study

  • Luis Fernando Méndez-López

      Affiliations

    • División de Genética, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Mexico
    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Monterrey, Mexico
    • ,
  • Pablo Zapata-Benavides

      Affiliations

    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Monterrey, Mexico
    • ,
  • Angel Zavala-Pompa

      Affiliations

    • Servicio de Anatomía Patológica, Unidad Médica de Alta Especialidad No. 25, Instituto Mexicano del Seguro Social, Monterrey, Mexico
    • ,
  • Miguel Elías Aguado-Barrera

      Affiliations

    • División de Genética, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Mexico
    • ,
  • Javier Pacheco-Calleros

      Affiliations

    • Servicio de Anatomía Patológica, Unidad Médica de Alta Especialidad No. 25, Instituto Mexicano del Seguro Social, Monterrey, Mexico
    • ,
  • Cristina Rodríguez-Padilla

      Affiliations

    • Departamento de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Monterrey, Mexico
    • ,
  • Ricardo Martín Cerda-Flores

      Affiliations

    • Facultad de Enfermería and Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Monterrey, Mexico
    • ,
  • Elva Irene Cortés-Gutiérrez

      Affiliations

    • División de Genética, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Mexico
    • ,
  • Martha Imelda Dávila-Rodríguez

      Affiliations

    • División de Genética, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Mexico
    • Corresponding Author InformationAddress reprint requests to: Martha Imelda Davila Rodriguez, División de Genética, Centro de Investigación Biomédica del Noreste, IMSS, 2 de abril No. 501, Colonia Independencia, CP 64720, Monterrey, Nuevo León, México. FAX: (01) (81) 8190-4035

Received 22 February 2010 ,Accepted 13 May 2010.

References 

  1. Sells SF, Wood DP, Joshi-Barve SS, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ. 1994;5:457–466
  2. Sells SF, Han SS, Muthukkumar S, et al. Expression and function of the leucine zipper protein par-4 in apoptosis. Mol Cell Biol. 1997;17:3823–3832
  3. El-Guendy N, Rangnekar VM. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res. 2003;283:51–66
  4. Gurumurthy S, Goswami A, Vasudevan KM, et al. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol. 2005;25:1146–1161
  5. Chakraborty M, Qiu SG, Vasudevan K, et al. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 2001;61:7255–7263
  6. Garcia-Cao I, Duran A, Collado M, et al. Tumour suppression activity of the proapoptotic regulator Par4. EMBO Rep. 2005;6:577–583
  7. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res. 2007;67:1927–1934
  8. Cook J, Krishnan S, Ananth S, et al. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene. 1999;18:1205–1208
  9. Goswami A, Burikhanov R, de Thonel A, et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell. 2005;20:33–44
  10. Zapata-Benavides P, Méndez-Vázquez JL, González-Rocha TR, et al. Expression of prostate apoptosis response (par-4) is associated with progesterone receptor in breast cancer. Arch Med Res. 2009;40:595–599
  11. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin. 2000;50:7–33
  12. Beckmann MW, Niederacher D, Schnurch HG, et al. Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Mol Med. 1997;75:429–439
  13. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer. 1982;45:361–366
  14. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207–219
  15. Tavassoli FA, Devilee P. World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs. Lyon, France: IARC Press; 2003;
  16. McDonald JW, Pilgram TK. Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma. Histopathology. 1999;34:439–446
  17. Estrada CR, Adam RM, Eaton SH, et al. Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder. Lab Invest. 2006;86:1293–1302
  18. Boghaert ER, Sells SF, Walid AJ, et al. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ. 1997;8:881–890
  19. Streuli CH, Haslam SZ. Control of mammary gland development and neoplasia by stromal-epithelial interactions and extracellular matrix. J Mamm Gland Biol Neoplasia. 1998;3:107–108
  20. Vogel PM, Georgiade NG, Fetter BF. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol. 1981;104:23–34
  21. Clark GM, McGuire WL. New biologic prognostic factors in breast cancer. Oncology. 1999;23:49–54
  22. Burikhanov R, Zhao Y, Goswami A, et al. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell. 2009;138:377–388
  23. El-Guendy N, Zhao Y, Gurumurthy S, et al. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol. 2003;23:5516–5525
  24. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat. 1994;32:39–47
  25. Goswami A, Burikhanov R, de Thonel A, et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell. 2005;20:33–44
  26. Li M, Hu J, Heermeier K, et al. Apoptosis and remodeling of mammary gland tissue during involution proceed through p53-independent pathways. Cell Growth Differ. 1996;7:13–20
  27. Shilkaitis A, Graves J, Mehta RR, et al. Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis. Cell Growth Differ. 2000;11:437–445
  28. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879–886
  29. Yang T, Buchan HL, Townsend KJ, et al. MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol. 1996;166:523–536
  30. Thomas A, Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996;12:1055–1062
  31. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene. 2000;19:6627–6631
  32. Cheema SK, Mishra SK, Rangnekar VM, et al. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem. 2003;278:19995–20005
  33. Qiu G, Ahmed M, Sells SF, et al. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene. 1999;18:623–631
  34. Bieberich E, MacKinnon S, Silva J, et al. Regulation of cell death in mitotic neural progenitor cells by asymmetric distribution of prostate apoptosis response 4 (PAR-4) and simultaneous elevation of endogenous ceramide. J Cell Biol. 2003;162:469–479
  35. Kögel D, Plöttner O, Landsberg G, et al. Cloning and characterization of Dlk, a novel serine/threonine kinase that is tightly associated with chromatin and phosphorylates core histones. Oncogene. 1998;19(17):2645–2654
  36. Diaz-Meco MT, Lallena MJ, Monjas A, et al. Inactivation of the inhibitory κB protein kinase/nuclear factor κB pathway by Par-4 expression potentiates tumor necrosis factor α induced apoptosis. J Biol Chem. 1999;274:19606–19612
  37. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6910–6924
  38. Stambolic V, Mak TW, Woodgett JR. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene. 1999;18:6094–6103
  39. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2002;100:57–70
  40. Denmeade SR, Isaacs JT. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol. 1996;35:281–306
  41. Ahmed MM, Sheldon D, Fruitwala MA, et al. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer. 2008;122:63–70
  42. Boehrer S, Chow KU, Puccetti E, et al. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J. 2001;2:103–107
  43. Faratian D, Barlett J. Predictive markers in breast cancer-the future. Histopathology. 2008;52:91–98

PII: S0188-4409(10)00131-1

doi: 10.1016/j.arcmed.2010.05.005

Archives of Medical Research
Volume 41, Issue 4 , Pages 261-268 , May 2010

Article Tools

* Image Usage & Resolution